Test for COVID‐19 patients with acute decompensation or acute‐on‐chronic liver and per institution’s practices
Persons with NAFLD likely to have comorbidity risk factors for severe COVID‐19
Consider patients with CLD/COVID‐19 for early admission and clinical trial
Use acetaminophen (2–3 g/day is generally safe)
Limit use of nonsteroidal anti‐inflammatory drugs
Test for COVID‐19 patients with acute decompensation or acute‐on‐chronic liver and per institution’s practices
Persons with NAFLD likely to have comorbidity risk factors for severe COVID‐19
Consider patients with CLD/COVID‐19 for early admission and clinical trial
Use acetaminophen (2–3 g/day is generally safe)
Limit use of nonsteroidal anti‐inflammatory drugs